Daclatasvir [1009119-64-5]

Cat# HY-10466-50mg

Size : 50mg

Brand : MedChemExpress

Request more information

Contact local distributor :


Phone : +1 850 650 7790

Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively.

For research use only. We do not sell to patients.

Daclatasvir Chemical Structure

Daclatasvir Chemical Structure

CAS No. : 1009119-64-5

This product is a controlled substance and not for sale in your territory.

Based on 50 publication(s) in Google Scholar

Other Forms of Daclatasvir:

  • Daclatasvir dihydrochloride In-stock
  • Daclatasvir-d6 Get quote
  • Daclatasvir-d16 Get quote

    Daclatasvir purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2018 Sep 18;14(9):e1007284.  [Abstract]

    Polyprotein expression efficiency is determined by Western-Blot using an antibody against NS3 and beta actin as loading control.

    Daclatasvir purchased from MedChemExpress. Usage Cited in: Eur J Med Chem. 2018 Jan 1;143:1053-1065.  [Abstract]

    GS4.3 cells are treated with 7f (20 μM), or Telaprevir (0.5μM), Sofosbuvir (0.8 μM), Daclatasvir (0.15 μM) or solvent control for 6 days.

    Daclatasvir purchased from MedChemExpress. Usage Cited in: Eur J Med Chem. 2018 Jan 1;143:1053-1065.  [Abstract]

    Huh7.5 cells are infected with HCV and simultaneously treated with 7f (10 μM) or DAA (0.04 μM Simeprevir, 0.08 μM Sofosbuvir, or 16 pM Daclatasvir) or 7f plus DAA.

    Daclatasvir purchased from MedChemExpress. Usage Cited in: Open Virol J. 2014 Mar 7;8:1-8.  [Abstract]

    The PKR activation block is not unique to CypI, DAAs also prevent the IFN-induced PKR activation in HCV-infected cells. JFH-1-infected Huh7.5.1 cells are treated with or without CypI (cyclosporine A and alisporivir), DAAs (the HCV NS5A inhibitor daclatasvir and the HCV protease inhibitor telaprevir) and an HIV-1 inhibitor (reverse transcriptase inhibitor emtricitabine). Results are representative of 4 independent experiments.
    Description

    Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively[1][2][3].

    IC50 & Target

    EC50: 50 pM (HCV replicon genotype 1a), 9 pM (HCV replicon genotype 1b), 71 pM (HCV replicon genotype 2a), 146 pM (HCV replicon genotype 3a), 12 pM (HCV replicon genotype 4a) and 33 pM (HCV replicon genotype 5a)[1]
    Kd: 8 nM (NS5A33-202) and 210 nM (NS5A26-202)[2]
    IC50: 1.5 µM (OATP1B) and 3.27 µM (OATP1B3)[3]

    Cellular Effect
    Cell Line Type Value Description References
    CCRF-CEM CC50
    9.6 μM
    Compound: BMS-790052
    Cytotoxicity against human CEM cells after 3 days
    Cytotoxicity against human CEM cells after 3 days
    [PMID: 22507961]
    Huh-7 CC50
    > 10 μM
    Compound: 33
    Cytotoxicity against human HuH7 cells infected with HCV1b by Alamar blue fluorescence assay
    Cytotoxicity against human HuH7 cells infected with HCV1b by Alamar blue fluorescence assay
    [PMID: 24521299]
    Huh-7 EC50
    0.003 nM
    Compound: 1, BMS-790052
    Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by cell-based replicon assay
    Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by cell-based replicon assay
    [PMID: 25148100]
    Huh-7 EC50
    0.009 nM
    Compound: 33
    Antiviral activity against HCV1b infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by FRET assay
    Antiviral activity against HCV1b infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by FRET assay
    [PMID: 24521299]
    Huh-7 EC50
    0.009 nM
    Compound: 6, BMS-790052
    Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by renilla luciferase reporter gene assay
    Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by renilla luciferase reporter gene assay
    [PMID: 24320933]
    Huh-7 EC50
    0.01 nM
    Compound: BMS, BMS-790052
    Antiviral activity against HCV 1b infected in human HuH7 cells by in vitro replicon assay
    Antiviral activity against HCV 1b infected in human HuH7 cells by in vitro replicon assay
    [PMID: 23466233]
    Huh-7 EC50
    0.023 nM
    Compound: 1a
    Inhibition of NS5A in HCV genotype-1b infected in human HuH7 cells by luciferase reporter gene assay
    Inhibition of NS5A in HCV genotype-1b infected in human HuH7 cells by luciferase reporter gene assay
    [PMID: 25453810]
    Huh-7 EC50
    0.05 nM
    Compound: 33
    Antiviral activity against HCV1a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by FRET assay
    Antiviral activity against HCV1a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by FRET assay
    [PMID: 24521299]
    Huh-7 EC50
    0.05 nM
    Compound: 6, BMS-790052
    Antiviral activity against HCV genotype 1a H77 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by renilla luciferase reporter gene assay
    Antiviral activity against HCV genotype 1a H77 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by renilla luciferase reporter gene assay
    [PMID: 24320933]
    Huh-7 EC50
    0.051 nM
    Compound: 1, BMS-790052
    Antiviral activity against HCV genotype 5a infected in human HuH7 cells by luciferase reporter gene assay
    Antiviral activity against HCV genotype 5a infected in human HuH7 cells by luciferase reporter gene assay
    [PMID: 25453811]
    Huh-7 EC50
    0.073 nM
    Compound: 1, BMS-790052
    Antiviral activity against HCV genotype 1b infected in human HuH7 cells by luciferase reporter gene assay
    Antiviral activity against HCV genotype 1b infected in human HuH7 cells by luciferase reporter gene assay
    [PMID: 25453811]
    Huh-7 EC50
    0.14 nM
    Compound: 1, BMS-790052
    Antiviral activity against HCV genotype 1a infected in human HuH7 cells by luciferase reporter gene assay
    Antiviral activity against HCV genotype 1a infected in human HuH7 cells by luciferase reporter gene assay
    [PMID: 25453811]
    Huh-7 EC50
    0.14 nM
    Compound: 1a
    Inhibition of NS5A in HCV genotype-1a infected in human HuH7 cells by luciferase reporter gene assay
    Inhibition of NS5A in HCV genotype-1a infected in human HuH7 cells by luciferase reporter gene assay
    [PMID: 25453810]
    Huh-7 EC50
    0.41 nM
    Compound: 1, BMS-790052
    Antiviral activity against HCV genotype 4a infected in human HuH7 cells by luciferase reporter gene assay
    Antiviral activity against HCV genotype 4a infected in human HuH7 cells by luciferase reporter gene assay
    [PMID: 25453811]
    Huh-7 EC50
    0.45 nM
    Compound: 1, BMS-790052
    Antiviral activity against HCV genotype 6a infected in human HuH7 cells by luciferase reporter gene assay
    Antiviral activity against HCV genotype 6a infected in human HuH7 cells by luciferase reporter gene assay
    [PMID: 25453811]
    Huh-7 EC50
    0.67 nM
    Compound: 1, BMS-790052
    Antiviral activity against HCV genotype 3a infected in human HuH7 cells by luciferase reporter gene assay
    Antiviral activity against HCV genotype 3a infected in human HuH7 cells by luciferase reporter gene assay
    [PMID: 25453811]
    Huh-7 EC50
    0.67 nM
    Compound: 1, BMS-790052
    Antiviral activity against HCV genotype 2a infected in human HuH7 cells by luciferase reporter gene assay
    Antiviral activity against HCV genotype 2a infected in human HuH7 cells by luciferase reporter gene assay
    [PMID: 25453811]
    Huh-7 EC50
    6.6 pM
    Compound: BMS-790052
    Antiviral activity against HCV1b infected in human HuH7 cells assessed as inhibition of viral replication by RT-PCR analysis
    Antiviral activity against HCV1b infected in human HuH7 cells assessed as inhibition of viral replication by RT-PCR analysis
    [PMID: 22507961]
    PBMC CC50
    19 μM
    Compound: BMS-790052
    Cytotoxicity against human PBMC after 3 days
    Cytotoxicity against human PBMC after 3 days
    [PMID: 22507961]
    Vero CC50
    21 μM
    Compound: BMS-790052
    Cytotoxicity against african green monkey Vero cells after 3 days
    Cytotoxicity against african green monkey Vero cells after 3 days
    [PMID: 22507961]
    In Vitro

    Daclatasvir (BMS-790052) demonstrates potent inhibitory activity towards all genotypes tested, with EC50 values ranging from 9 pM to 146 pM. Daclatasvir inhibits HCV replicon genotype 1a, 1b, 2a, 3a, 4a and 5a with EC50 values of 50 pM, 9 pM, 71 pM, 146 pM, 12 pM and 33 pM, respectively. Daclatasvir is a potent inhibitor of the JFH-1 genotype 2a infectious virus that replicates in cell culture (EC50=28 pM)[1]. Daclatasvir (BMS-790052) binds tightly to NS5A33-202 and NS5A26-202 with Kds of 8 nM and 210 nM, respectively[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Daclatasvir (BMS-790052; 30 mg/kg; oral administration; daily; for 27 days) treatment reduces serum HCV RNA titers very rapidly by ~1.5 log10 at day 3[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: NOD/SCID male mice (5 weeks of age, 18-20 g) bearing HCV RNA-transfected cells[4]
    Dosage: 30 mg/kg
    Administration: Oral administration; daily; for 27 days
    Result: Reduced serum HCV RNA titers very rapidly by ~1.5 log10 at day 3.
    Clinical Trial
    Molecular Weight

    738.88

    Formula

    C40H50N8O6

    CAS No.

    1009119-64-5

    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    O=C([C@@H](NC(OC)=O)C(C)C)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C5=CN=C([C@@H]6CCCN6C([C@@H](NC(OC)=O)C(C)C)=O)N5)C=C4

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 40 mg/mL (54.14 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.3534 mL 6.7670 mL 13.5340 mL
    5 mM 0.2707 mL 1.3534 mL 2.7068 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 98.76%

    References
    • [1]. Min Gao, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010 May 6;465(7294):96-100.  [Content Brief]

      [2]. David B Ascher, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Apr 23;4:4765.  [Content Brief]

      [3]. Tomomi Furihata, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014 Aug;58(8):4555-64.  [Content Brief]

      [4]. Seung-Hoon Lee, et al. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep. 2018 Aug 20;8(1):12469.  [Content Brief]

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.3534 mL 6.7670 mL 13.5340 mL 33.8350 mL
    5 mM 0.2707 mL 1.3534 mL 2.7068 mL 6.7670 mL
    10 mM 0.1353 mL 0.6767 mL 1.3534 mL 3.3835 mL
    15 mM 0.0902 mL 0.4511 mL 0.9023 mL 2.2557 mL
    20 mM 0.0677 mL 0.3383 mL 0.6767 mL 1.6917 mL
    25 mM 0.0541 mL 0.2707 mL 0.5414 mL 1.3534 mL
    30 mM 0.0451 mL 0.2256 mL 0.4511 mL 1.1278 mL
    40 mM 0.0338 mL 0.1692 mL 0.3383 mL 0.8459 mL
    50 mM 0.0271 mL 0.1353 mL 0.2707 mL 0.6767 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Daclatasvir Related Classifications

    Help & FAQs

    Keywords:

    Daclatasvir1009119-64-5BMS-790052 EBP 883BMS790052BMS 790052EBP883EBP 883EBP-883HCVHepatitis C virusNS5AreplicongenotypesantiviralJFH-1OATP1B1OATP1B3Inhibitorinhibitorinhibit

    You might also be interested by the following products:



    Cat#
    Description
    Cond.
    Price Bef. VAT
    HY-14542-10mg
     10mg 
    HY-15287-10mg
     10mg